No Data
SiriusXM CEO Jennifer Witz to Deliver C Space Keynote at CES 2025
Witz More Than Doubles Full-Year Profit
WITZ Corp. Reports Robust Financial Growth
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Matsushita <9601> 9246 -106 Lowered financial estimates for the fiscal year ending March 2025. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% from the previous year and by 19.6% for the current year. Albaitai <2341> 143 -8 The operating profit for the previous term decreased by 98.2%, expanding the profit decline rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the Phase 1 trial of the CLK inhibitor CTX-712.
WITZ To Go Ex-Dividend On August 28th, 2025 With 15 JPY Dividend Per Share
October 12th (Japan Standard Time) - $WITZ(4440.JP)$ is trading ex-dividend on August 28th, 2025.Shareholders of record on August 31st, 2025 will receive 15 JPY dividend per share. The ex-dividend
Active and newly established stocks in the afternoon session.
*Matsusho <9601> 9246 -106 Operating profit forecast for the fiscal year ending February 2025 revised downward. *Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% from the previous year and by 19.6% for the current year. *Alba-Tai <2341> 143 -8 Operating profit in the previous period decreased by 98.2%, expanding the decline rate from 80.3% in the first quarter. *Chordia <190A> 296 -38 Results of the phase 1 clinical trial of the CLK inhibitor CTX-712 announced at the Japanese Society of Hematology Annual Meeting. *Aer
No Data
No Data